Regulatory Aspects of Gene Therapy: The Regulatory Life Cycle.
Cell therapy
Food and drug administration (FDA)
Gene therapy
Pediatric
Regulations
Journal
Hematology/oncology clinics of North America
ISSN: 1558-1977
Titre abrégé: Hematol Oncol Clin North Am
Pays: United States
ID NLM: 8709473
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
pubmed:
1
7
2022
medline:
20
7
2022
entrez:
30
6
2022
Statut:
ppublish
Résumé
The recent progress in gene and gene-modified cellular therapies has shown great promise for numerous pediatric diseases. Nevertheless, the development of these products is complicated, and the regulatory pathway is rigorous. There are, however, several opportunities for programmatic support within the Food and Drug Administration. This article highlights the life cycle of product development through approval and many of the available resources and programs to support product development.
Identifiants
pubmed: 35773050
pii: S0889-8588(22)00025-9
doi: 10.1016/j.hoc.2022.03.004
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
687-699Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors have nothing to disclose.